Brazil to India Pharmaceutical Import

The pharmaceutical trade corridor between Brazil and India has experienced significant growth from 2022 to 2026. In 2022, the total import value was approximately $50 million USD, with 300 shipments from 50 Brazilian suppliers to 30 Indian buyers. By 2026, these figures escalated to a total import value of $200 million USD, encompassing 1,452 shipments from 155 Brazilian suppliers to 72 Indian buyers. This fourfold increase underscores the strengthening bilateral trade relations and India's growing reliance on Brazilian pharmaceutical products.

Brazil's contribution to India's pharmaceutical imports has become increasingly significant. In 2026, Brazil accounted for approximately 5% of India's total pharmaceutical imports, positioning it among the top ten suppliers. The primary categories imported from Brazil include insulin, vaccines, and other essential medications, reflecting Brazil's capacity to meet India's demand for both generic and specialized pharmaceutical products.

Between 2024 and 2026, several key developments have influenced the pharmaceutical trade between Brazil and India. In April 2024, the Central Drugs Standard Control Organisation (CDSCO) introduced streamlined procedures for the registration of foreign pharmaceutical products, facilitating easier market entry for Brazilian companies. Additionally, in January 2025, India and Brazil signed a bilateral trade agreement aimed at enhancing cooperation in the pharmaceutical sector, including joint ventures and technology sharing. These initiatives have contributed to the expansion of the trade corridor.

Brazilian pharmaceutical companies seeking to import products into India must navigate the CDSCO registration process. The initial step involves appointing an Authorized Indian Representative (AIR), as foreign manufacturers cannot apply directly. The AIR submits an Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, providing details about the applicant, manufacturing site, and product information. Essential documents include a Power of Attorney, Site Master File, and a Free Sale Certificate. The CDSCO reviews the application, which may involve site inspections, and issues a Registration Certificate upon approval. The entire process typically spans several months, depending on the complexity of the application.

India mandates that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Brazilian manufacturers must ensure their facilities comply with these standards, which encompass quality management systems, personnel qualifications, and production controls. The CDSCO conducts inspections to verify compliance, and a WHO prequalification is often required for certain products. Non-compliance can result in delays or rejections of import applications.

To import pharmaceutical products into India, Brazilian companies must secure an Import License (Form 10) from the CDSCO. This license authorizes the importation of specific products and is valid for a defined period. Additional documentation includes a Registration Certificate, No Objection Certificate (NOC) for dual-use goods, and a Test License for products intended for clinical trials or testing. Customs procedures require detailed product information, including labeling and packaging compliance with Indian regulations.

In 2026, insulin emerged as the dominant product category in India's pharmaceutical imports from Brazil, accounting for 80.7% of the total import value. This is followed by serum products at 7.6%, vaccines at 4.2%, and other medications such as dexamethasone and moxifloxacin, each contributing 2.0%. The prevalence of insulin imports aligns with India's substantial diabetic population and the need for specialized treatments.

Brazilian pharmaceutical companies have been instrumental in supplying innovative and specialty products to India. Notably, the importation of semaglutide, a novel GLP-1 receptor agonist for diabetes management, signifies the introduction of advanced therapies not widely available in India. Additionally, the importation of biologics and biosimilars from Brazil addresses India's demand for complex treatments, particularly in oncology and autoimmune diseases.

India's importation of pharmaceutical products from Brazil is driven by several factors. Patent protection in Brazil allows for the production of generic versions of patented drugs, offering cost-effective alternatives to Indian manufacturers. Technological gaps in India's pharmaceutical manufacturing capabilities necessitate the importation of specialized products. Brazil's adherence to international quality standards and its capacity to produce complex biologics further enhance its appeal as a supplier to the Indian market.

India's import tariff structure for pharmaceutical formulations includes a Most Favored Nation (MFN) tariff rate, basic customs duty, Integrated Goods and Services Tax (IGST), and a health cess. The MFN tariff rate is typically set at 10%, with a basic customs duty of 5%. The IGST is levied at 18%, and a health cess of 1% is applied on the total value of the imported goods. These duties collectively impact the pricing of imported pharmaceutical products, influencing the competitiveness of Brazilian exports in the Indian market.

As of March 2026, India and Brazil do not have a formal Free Trade Agreement (FTA) specifically covering pharmaceuticals. However, both countries are members of the Regional Comprehensive Economic Partnership (RCEP), which aims to reduce trade barriers among member nations. Bilateral negotiations have been ongoing to explore preferential duty rates and other trade facilitation measures in the pharmaceutical sector. These discussions seek to enhance trade flows and address regulatory harmonization challenges.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the rejection of patents on new forms of known substances unless they demonstrate enhanced efficacy. This provision has implications for the importation of certain pharmaceutical products from Brazil. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Price controls can affect the profitability of imported pharmaceutical products and influence the pricing strategies of Brazilian exporters.

Pharmaceutical shipments from Brazil to India primarily utilize sea routes, with major ports such as Santos and Rio de Janeiro in Brazil serving as departure points. These shipments typically transit through the Suez Canal, entering the Indian Ocean and arriving at ports like Mumbai and Chennai. The average transit time ranges from 30 to 40 days, depending on the specific ports and shipping lines used. Air freight options are also available, offering faster delivery times but at higher costs.

Key Brazilian export ports handling pharmaceutical shipments include Santos, Rio de Janeiro, and Paranaguá. In India, major import ports include Mumbai, Chennai, and Kolkata. These ports are equipped with facilities to handle pharmaceutical products, including temperature-controlled storage for sensitive items. However, infrastructure challenges such as congestion and limited capacity can impact the efficiency of logistics operations.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, inspection of goods, and payment of applicable duties and taxes. The CDSCO conducts quality testing to ensure compliance with Indian standards. For temperature-sensitive products, adherence to Good Distribution Practice (GDP) and cold chain management is mandatory. Failure to comply with these standards can result in delays, rejections, or destruction of goods.

Despite being a major pharmaceutical manufacturer, India imports a significant portion of its pharmaceutical products, particularly specialized and patented drugs. Brazil's capacity to produce high-quality generics and biologics fills critical gaps in India's domestic production capabilities. The importation of these products is essential to meet the diverse healthcare needs of India's large and growing population.

Major Brazilian pharmaceutical companies, such as M/S. NOVO NORDISK A/S, have established a strong presence in the Indian market. These companies employ strategies like direct exports, joint ventures, and partnerships with local distributors to enhance market penetration. Contract manufacturing agreements have also been explored to leverage India's manufacturing capabilities while ensuring compliance with local regulations.

India's Atmanirbhar Bharat initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. While these policies are expected to enhance India's self-reliance in pharmaceutical production, the demand for specialized and high-quality products from Brazil is likely to persist. Therefore, imports from Brazil may continue to grow, albeit at a potentially slower rate, as India strengthens its domestic capabilities.

India imports pharmaceutical products from various countries, including the USA, European Union, China, Switzerland, and Japan. In 2026,